Analysts Set DaVita Inc. (NYSE:DVA) Price Target at $161.80

DaVita Inc. (NYSE:DVA) has received an average recommendation of “Hold” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $161.80.

A number of equities analysts have recently weighed in on the company. Barclays upped their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial boosted their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th.

DaVita Stock Performance

NYSE:DVA opened at $153.02 on Friday. The stock has a market cap of $12.55 billion, a P/E ratio of 16.51, a price-to-earnings-growth ratio of 0.86 and a beta of 0.90. DaVita has a 1-year low of $103.40 and a 1-year high of $169.51. The stock’s 50-day moving average is $157.00 and its 200-day moving average is $150.97. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the firm posted $2.85 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities research analysts anticipate that DaVita will post 9.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Harvard Management Co. Inc. bought a new stake in shares of DaVita in the 2nd quarter worth approximately $55,115,000. KBC Group NV raised its position in shares of DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of DaVita by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after buying an additional 56,389 shares in the last quarter. Andra AP fonden boosted its holdings in DaVita by 9.0% in the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after buying an additional 15,800 shares during the period. Finally, abrdn plc grew its stake in DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after buying an additional 2,180 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.